Candela's Laser Tech Rewrites Aging, Redefining a $30B Market

MARLBOROUGH, MA – June 30, 2026 – In a move that sends ripples far beyond the aesthetics industry, medical device leader Candela has unveiled research that fundamentally alters our understanding of anti-aging treatments. A peer-reviewed study published today in the prestigious journal Scientific Reports provides the first human evidence that one of the company's lasers doesn't just improve the skin's appearance—it reverses key biological markers of aging at the epigenetic level.

This isn't merely a better way to treat wrinkles. The findings suggest that the Nordlys® non-ablative fractional laser can remodel the skin's core biology, offering durable, molecular-level rejuvenation. For investors and executives watching the multi-billion-dollar wellness and longevity space, this development signals a pivotal shift, elevating a cosmetic procedure into the realm of regenerative medicine and positioning Candela, backed by private equity firm Apax Partners, at the forefront of a new technological frontier.

Decoding the Science of Rejuvenation

For decades, the success of aesthetic treatments has been judged by the naked eye and before-and-after photos. Candela's latest research, conducted with skin-epigenetics pioneer Mitra Bio, looks far deeper. The study focused on DNA methylation, a key epigenetic mechanism. Think of your DNA as the hardware of a computer; epigenetics is the software that tells the hardware which programs to run. As we age, this 'software' accumulates errors, leading to changes in gene expression that manifest as signs of aging.

The study's design was meticulous. In a split-face trial involving 22 adults, one side of the face was treated with the Nordlys laser while the other served as a control. Researchers analyzed over 3.8 million epigenetic sites per sample over nine months. The results were striking: at a staggering 83.9% of the sites most strongly associated with skin aging, the laser treatment shifted DNA methylation patterns back toward a more youthful state.

"Epigenetic patterns are among the most reliable molecular markers for measuring aging," stated Dr. Cristiana Banila, Chief Scientific Officer of Mitra Bio and a study co-author. "We found that the changes were not only directional, opposing the patterns we associate with aging, but also durable and strengthening over months. That combination is what makes these results scientifically compelling."

These molecular changes were not just theoretical. They directly correlated with visible improvements, including a median 38% reduction in brown spots and enhanced skin texture. The effects were also lasting, with the epigenetic reversal emerging one month after treatment, expanding at three months, and remaining stable at the six-month mark. This demonstrates a durable biological impact, a critical factor for both patient satisfaction and clinical value.

Beyond Aesthetics: A New Frontier in Skin Health

Perhaps the most groundbreaking aspect of the study is a finding that transcends aesthetics entirely: a direct molecular link to skin cancer biology. The research revealed that the Nordlys laser positively modulates genes known to be involved in the development of basal and squamous cell carcinomas, the most common forms of skin cancer. By influencing these pathways, the treatment may offer a previously unimagined preventative health benefit.

This adds a powerful new dimension to the value proposition of aesthetic technology. The findings support prior, separate research, such as a 2023 study in Dermatologic Surgery, which found that similar laser treatments were associated with a decreased risk of developing keratinocyte carcinomas. Candela's study now provides a potential molecular explanation for that observed clinical benefit.

"Physicians have seen that Nordlys treatments do more than improve the skin's appearance and until now, we could not fully explain why," said Dr. Konika Patel Schallen, lead author and a senior vice president at Candela. "For the first time, we have evidence of the molecular mechanism behind why skin is healthier and appears more youthful. Importantly, it also points to a molecular link to skin cancer biology."

This dual-action potential—cosmetic enhancement paired with a possible reduction in cancer risk—could reshape patient and physician decision-making, transforming an elective procedure into a proactive health and wellness strategy.

Candela's Strategic Edge in a Booming Market

The medical aesthetics market is a juggernaut, projected to exceed $30 billion by 2031, with energy-based devices like lasers commanding the largest share. In this fiercely competitive landscape, which includes major players like Lumenis, Cutera, and Cynosure, true differentiation is paramount. With this study, Candela has fortified its competitive moat not just with new features, but with fundamental scientific validation that redefines the category.

Geoff Crouse, Candela's Chief Executive Officer, framed the research as a core part of the company's strategy. "For decades, the industry has measured treatment success by the visible treatment impact," he said. "This research quantifies visible improvements and demonstrates the impact of the Nordlys system on skin biology. We are proud Candela continues to lead the conversation beyond the cosmetic realm and into regenerative medicine, skin health, and longevity."

By substantiating its technology's impact on the epigenome, the company is effectively creating a new premium tier in the market, one defined by biological outcomes rather than just surface-level results. This move could command higher price points, drive device sales, and establish a new benchmark that competitors will be forced to address. For Apax Partners, which acquired the device maker in 2017, this innovation validates its investment thesis and positions Candela as a leader not just in aesthetics, but in the high-growth longevity sector.

The implications are clear: the line between looking good and being well is blurring, powered by technologies that can influence our very biology. By proving its laser can turn back the skin's epigenetic clock, Candela has not only enhanced its product—it has provided a glimpse into the future of medicine, where treatments simultaneously renew and protect.